BRIDGE: Proactive Psychiatry Consultation and Case Management for Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03360695

Recruitment Status : Recruiting

First Posted : December 4, 2017

Last Update Posted : February 1, 2018

See Contacts and Locations

Sponsor:

Collaborator:

Harvard Risk Management Foundation

Information provided by (Responsible Party):

Kelly Edwards Irwin, Massachusetts General Hospital

Study Description

Brief Summary:

The purpose of this research is to understand if it is helpful for patients with mental illness to be connected to a psychiatrist and case manager at the time of cancer diagnosis.

Condition or disease	Intervention/treatment	Phase
Cancer Severe Major Depression Schizophrenia Bipolar Disorder Lung Cancer Breast Cancer Head and Neck Cancer Gastrointestinal Cancer	Other: Proactive Psychiatry Consultation	Not Applicable

Detailed Description:

It is challenging to cope with cancer. The investigators want to understand if it is helpful for patients with serious mental illness (SMI) to be connected to a psychiatrist and case manager when cancer is diagnosed. Many people with illnesses like major depression, schizophrenia and bipolar disorder face barriers to receiving high quality cancer care. It can be difficult to get to appointments, have many different doctors, and experience depression or worry. Better communication between the patient, the oncology team, and mental health providers may improve care. As for all patients, it is important for people with mental illness to have access to high quality cancer treatment that is patient-centered and coordinated. Having a case manager and psychiatrist at the cancer center who collaborates with the oncology team starting at cancer diagnosis may help patients to receive the cancer care that they need. This single-arm open pilot study will enable the study team to pilot patient measures (engagement and satisfaction in care, psychiatric and cancer-related symptoms) and caregiver measures (engagement and satisfaction in care, caregiver burden, and mastery) and refine the intervention manual before conducting a randomized controlled trial (17-396-RCT).

Study Design


Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	9 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Supportive Care
Official Title:	BRIDGE: Proactive Psychiatry Consultation and Case Management for Patients With Cancer
Actual Study Start Date :	December 11, 2017
Estimated Primary Completion Date :	March 30, 2018
Estimated Study Completion Date :	July 30, 2018

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Bipolar disorder Depression Schizophrenia

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Proactive Psychiatry Consultation (PPC) Proactive Psychiatry Consultation and Case Management is: Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity. Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care. Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment. Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed.	Other: Proactive Psychiatry Consultation Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.

Arm

Intervention/treatment

Experimental: Proactive Psychiatry Consultation (PPC)

Proactive Psychiatry Consultation and Case Management is:

Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.
Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.
Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.
Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed.

Other: Proactive Psychiatry Consultation

Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.

Outcome Measures

Primary Outcome Measures :

Feasibility of intervention delivery [ Time Frame: 12 weeks ]
60% of enrolled patients complete the intervention:
1. Patient completes interdisciplinary assessment and has at least 2 additional interactions with the intervention team
2. Intervention team communicates with oncology team at least once
3. If caregiver identified, intervention team communicates with caregiver at least once

Secondary Outcome Measures :

Acceptability of the intervention [ Time Frame: 12 weeks ]
The intervention will be evaluated as acceptable to patients if 60% of patients rate the intervention as acceptable (at least 4/5 on a 5 point scale) in exit surveys

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Patient Inclusion Criteria:

Age > 18 years old
Verbal fluency in English
SMI (Schizophrenia spectrum disorder, bipolar disorder, or major depressive disorder with prior psychiatric hospitalization) confirmed by diagnostic evaluation of study psychiatrist
Invasive breast, lung, gastrointestinal, or head and neck cancer (suspected or confirmed according to documentation by the oncologist or pathology)
Oncology consultation at Massachusetts General Hospital (MGH) Cancer Center within the past 8 weeks

Patient Exclusion Criteria:

Have cognitive impairment severe enough to interfere with completing brief study assessments or providing informed consent (and does not have a guardian who can provide consent)
Refuse participation

Caregiver Participants

Age > 18 years old
Verbal fluency in English
Family or community-based caregiver who accompanies the patient to medical appointments or participates in decision-making about cancer care
Patient participant identifies or confirms caregiver's involvement, provides permission to contact caregiver

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03360695

Contacts


Contact: Kelly E Irwin, MD	617-643-4453	keirwin@partners.org

Locations


United States, Massachusetts
Massachusetts General Hospital	Recruiting
Boston, Massachusetts, United States, 02114
Contact: Kelly E Irwin, MD 617-643-4453 keirwin@partners.org
Principal Investigator: Kelly E Irwin, MD

Sponsors and Collaborators

Massachusetts General Hospital

Harvard Risk Management Foundation

Investigators


Principal Investigator:	Kelly E Irwin, MD	Massachusetts General Hospital

More Information


Responsible Party:	Kelly Edwards Irwin, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT03360695 History of Changes
Other Study ID Numbers:	17-396
First Posted:	December 4, 2017 Key Record Dates
Last Update Posted:	February 1, 2018
Last Verified:	January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No


Studies a U.S. FDA-regulated Drug Product:		No
Studies a U.S. FDA-regulated Device Product:		No

Keywords provided by Kelly Edwards Irwin, Massachusetts General Hospital:


Cancer Care Major Depression and Cancer Schizophrenia and Cancer Bipolar Disorder and Cancer Lung Cancer Breast Cancer	Head and Neck Cancer Gastrointestinal Cancer Schizophrenia Bipolar Disorder Major Depression

Additional relevant MeSH terms:


Depression Schizophrenia Head and Neck Neoplasms Bipolar Disorder Depressive Disorder, Major Gastrointestinal Neoplasms Behavioral Symptoms Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders	Neoplasms by Site Neoplasms Bipolar and Related Disorders Depressive Disorder Mood Disorders Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases

To Top